Issue 28, 2017, Issue in Progress
From the journal:

RSC Advances

Further correction: Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy

Vaibhav Khare,ab   Wejdan Al. Sakarchi,a   Prem N. Gupta,b   Anthony D. M. Curtisa  and  Clare Hoskins*a  

* Corresponding authors

a Institute of Science and Technology in Medicine, Keele University, Keele, Staffordshire, UK
E-mail: c.hoskins@keele.ac.uk

b Formulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, India 180001

Abstract

Further correction for ‘Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy’ by Vaibhav Khare et al., RSC Adv., 2016, 6, 60126–60137.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/C7RA90041D
Article type
Correction
Submitted
09 Mar 2017
Accepted
09 Mar 2017
First published
20 Mar 2017
This article is Open Access
Creative Commons BY license

RSC Adv., 2017,7, 17367-17367

Permissions

Request permissions

Further correction: Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy

V. Khare, W. Al. Sakarchi, P. N. Gupta, A. D. M. Curtis and C. Hoskins, RSC Adv., 2017, 7, 17367 DOI: 10.1039/C7RA90041D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements